Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Apellis Pharmaceuticals, Inc is a biotechnology business based in the US. Apellis Pharmaceuticals shares (APLS) are listed on the NASDAQ and all prices are listed in US Dollars. Apellis Pharmaceuticals employs 297 staff and has a market cap (total outstanding shares value) of USD$2.5 billion.
Since the stock market crash in March caused by coronavirus, Apellis Pharmaceuticals's share price has had significant positive movement.
Its last market close was USD$38.43, which is 4.06% up on its pre-crash value of USD$36.87 and 128.07% up on the lowest point reached during the March crash when the shares fell as low as USD$16.85.
If you had bought USD$1,000 worth of Apellis Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$550.66 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$885.43.
|Latest market close||USD$38.43|
|52-week range||USD$16.85 - USD$45.04|
|50-day moving average||USD$31.8723|
|200-day moving average||USD$31.3771|
|Wall St. target price||USD$51.62|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.322|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-18)||-7.58%|
|1 month (2020-10-26)||7.17%|
|3 months (2020-08-25)||32.93%|
|6 months (2020-05-22)||10.15%|
|1 year (2019-11-25)||36.86%|
|2 years (2018-11-23)||138.55%|
|3 years (2017-11-24)||182.57%|
|5 years (2015-11-22)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-41.1%|
|Return on equity TTM||-240.56%|
|Market capitalisation||USD$2.5 billion|
TTM: trailing 12 months
There are currently 10.9 million Apellis Pharmaceuticals shares held short by investors – that's known as Apellis Pharmaceuticals's "short interest". This figure is 3.8% up from 10.5 million last month.
There are a few different ways that this level of interest in shorting Apellis Pharmaceuticals shares can be evaluated.
Apellis Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Apellis Pharmaceuticals shares currently shorted divided by the average quantity of Apellis Pharmaceuticals shares traded daily (recently around 622651.2). Apellis Pharmaceuticals's SIR currently stands at 17.5. In other words for every 100,000 Apellis Pharmaceuticals shares traded daily on the market, roughly 17500 shares are currently held short.
However Apellis Pharmaceuticals's short interest can also be evaluated against the total number of Apellis Pharmaceuticals shares, or, against the total number of tradable Apellis Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Apellis Pharmaceuticals's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Apellis Pharmaceuticals shares in existence, roughly 140 shares are currently held short) or 0.221% of the tradable shares (for every 100,000 tradable Apellis Pharmaceuticals shares, roughly 221 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Apellis Pharmaceuticals.
Find out more about how you can short Apellis Pharmaceuticals stock.
We're not expecting Apellis Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Apellis Pharmaceuticals's shares have ranged in value from as little as $16.85 up to $45.04. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Apellis Pharmaceuticals's is 1.1483. This would suggest that Apellis Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin disease, C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company is also developing APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration. Apellis Pharmaceuticals, Inc. was founded in 2009 and is based in Waltham, Massachusetts.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.